Accuray and Erasmus Medical Center Sign Master Research and Collaboration
Agreement
Partnership Creates Strategic Alliance for Advancement of Research in Radiation
Oncology in the Netherlands
SUNNYVALE, Calif., June 26, 2012 /PRNewswire via COMTEX/ -- Accuray Incorporated
(ARAY), the premier radiation oncology company, announced today the signing of a
multi-year master research and collaboration agreement with Erasmus Medical
Center (MC), a leading research center in Rotterdam, the Netherlands and the
largest of the eight university medical centers in the country. Accuray and
Erasmus MC will partner on cutting-edge research in radiation oncology with the
goal of advancing treatment technology and providing healthcare professionals
with the most effective tools for patient care.
"Erasmus MC has a long history of collaborating with Accuray and we are pleased
to continue our partnership to advance radiation oncology," said Professor Peter
C. Levendag, M.D., Ph.D., Chairman of the Radiation Oncology Department at
Erasmus MC. "Our Center's extensive technical research and clinical experience
with the CyberKnife System has helped us see and understand the many benefits
that radiosurgery offers to cancer patients. We are pleased to reaffirm our
commitment to working together to further validate the science of radiosurgery
and clinical applications of the CyberKnife System."
Accuray has been working together with Erasmus MC on research initiatives since
the Center installed its first CyberKnife? Robotic Radiosurgery System in 2004,
making them the fourth site in the Europe India Middle East and Africa (EIMEA)
region to install a CyberKnife System at that time. To date, Erasmus MC has
treated more than 1,000 patients with the CyberKnife System, performed a
substantial amount of clinical research on the use of the CyberKnife System, and
authored more than 20 technical and clinical publications in peer-reviewed
journals and several book chapters. The Center has used novel research methods to
evaluate the performance of the CyberKnife System, including an assessment of the
impact of intra-fraction patient motion on clinical tracking accuracy, clinical
tracking accuracy of lung treatments using the Synchrony? Respiratory Tracking
System, dose calculation accuracy assessments, and methods for reducing treatment
time. Currently, the Center is evaluating hypothetical path sets and assessing
the InTempo(TM) Adaptive Imaging System, which enhances the CyberKnife System's
ability to continually track and correct for motion of the prostate during
treatment.
"As one of the world's foremost academic oncology research centers, Erasmus MC is
an important partner for us in advancing the use of the CyberKnife System," said
Euan S. Thomson, Ph.D., Accuray president and chief executive officer. "Our
collaboration will support the growing body of clinical evidence demonstrating
the efficacy and benefits of the CyberKnife System and help us further expand,
refine and customize cancer patient treatment. With the support of partners like
Erasmus MC, Accuray is poised to lead the charge toward truly personalized
radiation oncology."
In the last quarter, Accuray announced two additional research and collaboration
agreements including a multi-year master research and collaboration agreement
with the University of Heidelberg and the German Cancer Research Center
(Deutsches Krebsforschungszentrum, DKFZ), both luminary research institutions
located in Heidelberg, Germany.
About Erasmus MCErasmus MC is the largest and most authoritative scientific
University Medical Center in the Netherlands. Almost 13,000 staff members work
within the core tasks of patient care, education, and scientific research on the
continuous improvement and enforcement of individual patient care and social
healthcare. They develop high-level knowledge, pass this on to future
professionals, and apply it in everyday patient care. Over the next five years,
Erasmus MC wants to grow into one of the best medical institutes in the world.
Erasmus MC is part of the Dutch Federation of University Medical Centers (NFU):
nfu.nl. 
About AccurayAccuray Incorporated (ARAY), based in Sunnyvale, Calif., is the
premier radiation oncology company that develops, manufactures and sells
personalized innovative treatment solutions that set the standard of care, with
the aim of helping patients live longer, better lives. The Company's leading edge
technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver
radiosurgery, stereotactic body radiation therapy, intensity modulated radiation
therapy, image guided radiation therapy, and adaptive radiation therapy. To date
635 systems have been installed in leading hospitals around the world. For more
information, please visit accuray.com. |
